CN112816698A - Buffer reagent for improving detection clinical correlation and latex immunoturbidimetry kit - Google Patents
Buffer reagent for improving detection clinical correlation and latex immunoturbidimetry kit Download PDFInfo
- Publication number
- CN112816698A CN112816698A CN201911132994.1A CN201911132994A CN112816698A CN 112816698 A CN112816698 A CN 112816698A CN 201911132994 A CN201911132994 A CN 201911132994A CN 112816698 A CN112816698 A CN 112816698A
- Authority
- CN
- China
- Prior art keywords
- buffer
- concentration
- reagent
- detection
- kit
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003153 chemical reaction reagent Substances 0.000 title claims abstract description 106
- 239000000872 buffer Substances 0.000 title claims abstract description 95
- 239000004816 latex Substances 0.000 title claims abstract description 60
- 229920000126 latex Polymers 0.000 title claims abstract description 60
- 238000001514 detection method Methods 0.000 title abstract description 73
- 239000003792 electrolyte Substances 0.000 claims abstract description 37
- 239000001763 2-hydroxyethyl(trimethyl)azanium Substances 0.000 claims abstract description 29
- 235000019743 Choline chloride Nutrition 0.000 claims abstract description 29
- 229960003178 choline chloride Drugs 0.000 claims abstract description 29
- SGMZJAMFUVOLNK-UHFFFAOYSA-M choline chloride Chemical group [Cl-].C[N+](C)(C)CCO SGMZJAMFUVOLNK-UHFFFAOYSA-M 0.000 claims abstract description 29
- 239000002245 particle Substances 0.000 claims abstract description 19
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 42
- 239000003381 stabilizer Substances 0.000 claims description 25
- 239000004094 surface-active agent Substances 0.000 claims description 22
- 239000003755 preservative agent Substances 0.000 claims description 21
- 239000011780 sodium chloride Substances 0.000 claims description 21
- 230000002335 preservative effect Effects 0.000 claims description 19
- 101710198144 Endopolygalacturonase I Proteins 0.000 claims description 18
- 101710191566 Probable endopolygalacturonase I Proteins 0.000 claims description 18
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 claims description 17
- 239000002981 blocking agent Substances 0.000 claims description 16
- 239000007995 HEPES buffer Substances 0.000 claims description 15
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims description 14
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 claims description 13
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 claims description 13
- OOIBFPKQHULHSQ-UHFFFAOYSA-N (3-hydroxy-1-adamantyl) 2-methylprop-2-enoate Chemical compound C1C(C2)CC3CC2(O)CC1(OC(=O)C(=C)C)C3 OOIBFPKQHULHSQ-UHFFFAOYSA-N 0.000 claims description 12
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 11
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 11
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 11
- 102000014914 Carrier Proteins Human genes 0.000 claims description 9
- 241001529936 Murinae Species 0.000 claims description 9
- 108091008324 binding proteins Proteins 0.000 claims description 9
- 108010092028 endopolygalacturonase II Proteins 0.000 claims description 9
- SFNALCNOMXIBKG-UHFFFAOYSA-N ethylene glycol monododecyl ether Chemical compound CCCCCCCCCCCCOCCO SFNALCNOMXIBKG-UHFFFAOYSA-N 0.000 claims description 8
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 7
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 7
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 7
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 claims description 6
- 238000012360 testing method Methods 0.000 claims description 6
- 239000008118 PEG 6000 Substances 0.000 claims description 5
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 claims description 5
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 claims description 5
- 239000012895 dilution Substances 0.000 claims description 5
- 238000010790 dilution Methods 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 210000002966 serum Anatomy 0.000 claims description 5
- 239000004353 Polyethylene glycol 8000 Substances 0.000 claims description 3
- 239000007983 Tris buffer Substances 0.000 claims description 3
- 239000013504 Triton X-100 Substances 0.000 claims description 3
- 229920004890 Triton X-100 Polymers 0.000 claims description 3
- 239000008363 phosphate buffer Substances 0.000 claims description 3
- 229940057838 polyethylene glycol 4000 Drugs 0.000 claims description 3
- 229940093429 polyethylene glycol 6000 Drugs 0.000 claims description 3
- 229940085678 polyethylene glycol 8000 Drugs 0.000 claims description 3
- 235000019446 polyethylene glycol 8000 Nutrition 0.000 claims description 3
- 238000003908 quality control method Methods 0.000 claims description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 3
- 102100031051 Cysteine and glycine-rich protein 1 Human genes 0.000 claims 1
- 230000035945 sensitivity Effects 0.000 abstract description 10
- 230000000694 effects Effects 0.000 abstract description 7
- 108010074051 C-Reactive Protein Proteins 0.000 description 14
- 102100032752 C-reactive protein Human genes 0.000 description 14
- 239000004005 microsphere Substances 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 10
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 10
- 239000006172 buffering agent Substances 0.000 description 10
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 8
- 238000011088 calibration curve Methods 0.000 description 8
- 150000003839 salts Chemical class 0.000 description 8
- 108010047320 Pepsinogen A Proteins 0.000 description 7
- 239000000427 antigen Substances 0.000 description 7
- 102000036639 antigens Human genes 0.000 description 7
- 108091007433 antigens Proteins 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 239000007853 buffer solution Substances 0.000 description 6
- 108090001072 Gastricsin Proteins 0.000 description 5
- 102000001554 Hemoglobins Human genes 0.000 description 5
- 108010054147 Hemoglobins Proteins 0.000 description 5
- 102000034255 Pepsinogen C Human genes 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 238000005457 optimization Methods 0.000 description 5
- 239000001103 potassium chloride Substances 0.000 description 4
- 235000011164 potassium chloride Nutrition 0.000 description 4
- 206010003694 Atrophy Diseases 0.000 description 3
- 239000004793 Polystyrene Substances 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 229960005070 ascorbic acid Drugs 0.000 description 3
- 235000010323 ascorbic acid Nutrition 0.000 description 3
- 239000011668 ascorbic acid Substances 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000037444 atrophy Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 229920002223 polystyrene Polymers 0.000 description 3
- BDOYKFSQFYNPKF-UHFFFAOYSA-N 2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid;sodium Chemical compound [Na].[Na].OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O BDOYKFSQFYNPKF-UHFFFAOYSA-N 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- 108060003393 Granulin Proteins 0.000 description 2
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 238000003149 assay kit Methods 0.000 description 2
- 150000001718 carbodiimides Chemical class 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 210000001268 chyle Anatomy 0.000 description 2
- 238000003759 clinical diagnosis Methods 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 2
- 229960001008 heparin sodium Drugs 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 229940028435 intralipid Drugs 0.000 description 2
- 239000002960 lipid emulsion Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 230000009471 action Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000036046 immunoreaction Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
Abstract
The invention relates to the field of immunodetection, and particularly provides a buffer reagent for improving clinical relevance of detection and a latex immunoturbidimetric kit. The buffer reagent for improving the detection clinical relevance comprises an electrolyte, wherein the electrolyte is choline chloride. The inventor finds that the addition of choline chloride in the buffer reagent for latex immunoturbidimetry can significantly improve the clinical relevance of the detection result and improve the detection accuracy. The buffer reagent is applied to latex immunoturbidimetry detection, is used as a first reagent in a detection reagent, and reacts with a second reagent containing antibody-coated latex particles, so that the clinical relevance of detection can be remarkably improved, and the effect of resisting interference of various interferents is also remarkable, thereby further improving the accuracy and the sensitivity of the detection kit.
Description
Technical Field
The invention relates to the field of immunodetection, in particular to a buffer reagent and a latex immunoturbidimetry kit for improving clinical relevance of detection.
Background
The latex immunoturbidimetry performs an immunoreaction on an antigen to be detected in a sample and a specific antibody coated on latex microspheres in a detection reagent to form an immune complex, so that the latex microspheres are connected into a net shape, and the turbidity of a reaction solution system is increased. The turbidity is in positive correlation with the concentration of the antigen to be detected in the sample within a certain range, so the content of the antigen to be detected in the sample can be calculated by measuring the absorbance of a reaction system with a specific wavelength (570nm) and referring to a calibration curve. Compared with other detection methods, the latex immunoturbidimetry method has the advantages of large flux, short time consumption, capability of realizing automation, reduction of the influence of human factors on the detection result, and good sensitivity and accuracy. Therefore, the latex immunoturbidimetry has a good application prospect.
However, the latex immunoturbidimetry kits of various projects in the current market still have the problems of poor reagent specificity and anti-interference capability and the like, so that the accuracy of clinical detection results is influenced. Therefore, how to improve the clinical relevance value of the latex immunoturbidimetric detection reagent is further researched, which has important significance for the improvement of the immunodiagnosis method.
In view of the above, the present invention is particularly proposed.
Disclosure of Invention
The invention aims to provide a buffer reagent for improving clinical relevance of detection and a latex immunoturbidimetric kit applying the buffer reagent, and aims to solve the problems that the clinical relevance of a detection result is poor, and the specificity, the sensitivity and the anti-interference capability are to be improved when a latex immunoturbidimetric method is adopted for detection in the prior art.
In order to achieve the above purpose of the present invention, the following technical solutions are adopted:
a buffer reagent for improving the clinical relevance of a test, the buffer reagent comprising an electrolyte, the electrolyte being choline chloride.
Further, the concentration of the choline chloride is 200-400 mmol/L;
preferably, the buffer reagent further comprises at least one of a buffer, a blocking agent, a surfactant, a sensitizer, a stabilizer, and a preservative.
Further, the buffer comprises HEPES buffer, PB buffer, PBS buffer, Tris buffer or phosphate buffer;
preferably, the blocking agent comprises at least one of RF and HAMA binding protein, murine IgG, murine IgM, and murine serum;
preferably, the surfactant comprises Brij35, tween 20 or triton X-100;
preferably, the sensitizer comprises polyethylene glycol 4000, polyethylene glycol 6000 or polyethylene glycol 8000;
preferably, the stabilizer comprises disodium ethylenediaminetetraacetate, BSA, or trehalose;
preferably, the preservative comprises Proclin300 or sodium azide.
Further, the buffer solution comprises HEPES buffer solution or PB buffer solution, the pH value of the buffer solution is preferably in the range of 6-8, and the concentration of the buffer solution is preferably 10-200 mmol/L;
preferably, the blocking agent comprises RF and HAMA binding protein, preferably the concentration of blocking agent is 4-6 g/L;
preferably, the RF and HAMA binding proteins include HIER-E-010;
preferably, the surfactant comprises Brij35, and the concentration of the surfactant is preferably 0.5-1.5 g/L;
preferably, the sensitizer comprises PEG6000, and the concentration of the sensitizer is preferably 15-25 g/L;
preferably, the stabilizer comprises disodium ethylene diamine tetraacetate, and the concentration of the stabilizer is preferably 0.5-1.5 g/L;
preferably, the concentration of the preservative is 0.5-1.5 g/L.
The buffer reagent is applied to a latex immunoturbidimetry method or the preparation of a latex immunoturbidimetry kit.
A latex immunoturbidimetry kit comprises a first reagent and a second reagent, wherein the first reagent is the buffer reagent.
Further, the second reagent comprises a buffer, a preservative, antibody-coated latex particles, a stabilizer, and an electrolyte;
preferably, the buffer comprises a HEPES buffer, the pH of the buffer is preferably in the range of 6-8, and the concentration of the buffer is preferably 30-70 mmol/L;
preferably, the concentration of the preservative is 0.5-1.5 g/L;
preferably, the stabilizing agent comprises BSA and trehalose, wherein the concentration of the BSA is preferably 4-6g/L, and the concentration of the trehalose is preferably 35-45 g/L;
preferably, the electrolyte comprises sodium chloride, and the concentration of the electrolyte is preferably 150-250 mmol/L.
Further, the antibody in the antibody-coated latex particle comprises a PG i antibody, a PG II antibody, or a CRP antibody;
preferably, the concentration of the antibody-coated latex particles is 2-3 g/L.
Further, the kit also comprises a calibrator and a quality control product.
Further, the diluent of the calibrator comprises a buffer solution, a surfactant, a preservative, an electrolyte and a stabilizer;
preferably, the buffer comprises a HEPES buffer, the pH of the buffer is preferably in the range of 6-8, and the concentration of the buffer is preferably 30-70 mmol/L;
preferably, the surfactant comprises tween 20, and the concentration of the surfactant is preferably 0.5-1.5 g/L;
preferably, the concentration of the preservative comprises 0.5-1.5 g/L;
preferably, the electrolyte comprises sodium chloride, and the concentration of the electrolyte is preferably 150-250 mmol/L;
preferably, the stabilizing agent comprises BSA and disodium ethylene diamine tetraacetate, the concentration of the BSA is preferably 2-4g/L, and the concentration of the disodium ethylene diamine tetraacetate is preferably 0.5-1.5 g/L.
Compared with the prior art, the invention has the beneficial effects that:
the invention provides a buffer reagent for improving clinical relevance detection, which comprises an electrolyte, wherein the electrolyte is choline chloride. The inventor finds that the addition of choline chloride in the buffer reagent for latex immunoturbidimetry can significantly improve the clinical relevance of the detection result and improve the detection accuracy. In addition, the inventor proves through experiments that the buffer reagent provided by the invention has good universality, can improve the clinical relevance of detection in various detection items, and can be widely applied to various latex immunoturbidimetric detection items. The buffer reagent is applied to latex immunoturbidimetry detection, is used as a first reagent in a detection reagent, reacts with a second reagent containing antibody coated latex particles, can obviously improve the clinical relevance of detection, and has obvious effects on bilirubin interference resistance, vitamin C interference resistance, Intralipid fat emulsion interference resistance, hemoglobin interference resistance, ethylene diamine tetraacetic acid disodium interference resistance and heparin sodium interference resistance, thereby further improving the accuracy and sensitivity of the detection kit.
Drawings
In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings used in the description of the embodiments or the prior art will be briefly described below, and it is obvious that the drawings in the following description are some embodiments of the present invention, and other drawings can be obtained by those skilled in the art without creative efforts.
FIG. 1 is a calibration curve in example 3 of the present invention;
FIG. 2 is a linear correlation curve in example 3 of the present invention;
FIG. 3 is a graph showing the results of clinical correlations in example 4 of the present invention;
FIG. 4 is a graph showing the results of clinical correlation of 100mmol/L choline chloride buffer in example 5 of the present invention;
FIG. 5 is a graph showing the results of clinical correlation of 200mmol/L choline chloride buffer in example 5 of the present invention;
FIG. 6 is a graph showing the results of clinical correlation between 300mmol/L choline chloride buffer in example 5 of the present invention;
FIG. 7 is a graph showing the results of clinical correlation between 400mmol/L choline chloride buffer in example 5 of the present invention;
FIG. 8 is a graph showing the results of clinical correlation of 100mmol/L NaCl buffering agent in example 5 of the present invention;
FIG. 9 is a graph showing the results of clinical correlation of 200mmol/L NaCl buffering agent in example 5 of the present invention;
FIG. 10 is a graph showing the results of clinical correlation of 300mmol/L NaCl buffering agent in example 5 of the present invention;
FIG. 11 is a graph showing the results of clinical correlation between 400mmol/L NaCl buffering agent in example 5 of the present invention;
FIG. 12 is a graph showing the results of clinical correlation between 300mmol/L choline chloride buffer PG II in example 7 of the present invention;
FIG. 13 is a graph showing the results of clinical correlation between 300mmol/L NaCl buffering agent PG II in example 7 of the present invention;
FIG. 14 is a graph showing the results of clinical correlation between 300mmol/L potassium chloride buffer PG II in example 7 of the present invention;
FIG. 15 is a graph showing the results of clinical correlation between CRP as a 300mmol/L choline chloride buffering agent in example 7 of the present invention;
FIG. 16 is a graph showing the results of clinical correlation between CRP and 300mmol/L NaCl buffering agent in example 7 of the present invention;
FIG. 17 is a chart showing the results of clinical correlation between CRP as a 300mmol/L potassium chloride buffering agent in example 7 of the present invention.
Detailed Description
Embodiments of the present invention will be described in detail below with reference to examples, but it will be understood by those skilled in the art that the following examples are only illustrative of the present invention and should not be construed as limiting the scope of the present invention. The examples, in which specific conditions are not specified, were conducted under conventional conditions or conditions recommended by the manufacturer.
Unless otherwise defined, technical and scientific terms used herein have the same meaning as is familiar to those skilled in the art. In addition, any methods or materials similar or equivalent to those described herein can also be used in the present invention.
A buffer reagent for improving the clinical relevance of detection comprises an electrolyte, wherein the electrolyte is choline chloride.
The inventor finds that the addition of choline chloride in the buffer reagent for latex immunoturbidimetry can significantly improve the clinical relevance of the detection result and improve the detection accuracy. In addition, the inventor proves through experiments that the buffer reagent provided by the invention has good universality, can improve the clinical relevance of detection in various detection items, and can be widely applied to various latex immunoturbidimetric detection items. The buffer reagent is applied to latex immunoturbidimetry detection, is used as a first reagent in a detection reagent, reacts with a second reagent containing antibody coated latex particles, can obviously improve the clinical relevance of detection, and has obvious effects on bilirubin interference resistance, vitamin C interference resistance, Intralipid fat emulsion interference resistance, hemoglobin interference resistance, ethylene diamine tetraacetic acid disodium interference resistance and heparin sodium interference resistance, thereby further improving the accuracy and sensitivity of the detection kit.
In a preferred embodiment, the concentration of choline chloride is 200-400 mmol/L. The inventor finds that the detection effect is better when the concentration of the choline chloride is in the range of 200-400mmol/L, the clinical relevance is remarkable, and the concentration of the choline chloride is typically, but not limited to, 200mmol/L, 250mmol/L, 300mmol/L, 350mmol/L or 400 mmol/L.
In a preferred embodiment, the buffering agent comprises at least one of a buffer, a blocking agent, a surfactant, a sensitizer, a stabilizer, and a preservative in addition to the electrolyte choline chloride.
In preferred embodiments, the buffer comprises HEPES buffer, PB buffer, PBs buffer, Tris buffer, or phosphate buffer.
In preferred embodiments, the blocking agent comprises at least one of RF (rheumatoid factor) and HAMA (heterophilic antibody) binding protein, murine IgG, murine IgM, and murine serum.
In a preferred embodiment, the surfactant comprises Brij35, Tween 20, or Triton X-100.
In preferred embodiments, the sensitizer comprises polyethylene glycol 4000, polyethylene glycol 6000 or polyethylene glycol 8000.
In a preferred embodiment, the stabilizer comprises disodium ethylenediaminetetraacetate, BSA or trehalose.
In a preferred embodiment, the preservative comprises Proclin300 or sodium azide.
In the invention, other components of the buffer reagent are optimized, for example, the selection of the blocking agent solves the technical problem of poor RF and HAMA interference resistance in latex immunoturbidimetric detection in the prior art, thereby further improving the accuracy and sensitivity of the detection kit; the matching of the components such as the electrolyte, the surfactant, the sensitizer and the like ensures that the buffer reagent has good detection specificity, high sensitivity and strong anti-interference capability, and can accurately and quickly obtain the content of the antigen to be detected.
In a preferred embodiment, the buffer comprises a HEPES buffer or PB buffer, the pH of the buffer preferably ranges from 6 to 8, and the concentration of the buffer preferably ranges from 10 to 200 mmol/L; the blocking agent preferably comprises RF and HAMA binding protein, and the concentration of the blocking agent is preferably 4-6g/L, wherein the RF and HAMA binding protein comprises HIER-E-010; the surfactant preferably comprises Brij35, and the concentration of the surfactant is preferably 0.5-1.5 g/L; the sensitizer preferably comprises PEG6000, and the concentration of the sensitizer is preferably 15-25 g/L; the stabilizer comprises disodium ethylene diamine tetraacetate, and the concentration of the stabilizer is preferably 0.5-1.5 g/L; the concentration of the preservative is preferably 0.5 to 1.5 g/L. The inventor finds that the combination of the selection and the proportion of the components leads the clinical relevance of latex immunoturbidimetry detection to be better, and the accuracy and the sensitivity to be improved.
It should be noted that HIER-E-010 is a blocking agent sold under the trade name HIER-E-010 by Fipeng Bio Inc.
In a more preferred embodiment, the buffering agent comprises: 100mmol/L HEPES buffer solution, 5g/L HIER-E-010, 300mmol/L choline chloride, 1g/L Brij35, 20g/L PEG6000, 1g/L disodium ethylene diamine tetraacetate and 1g/L Proclin 300. The inventor finds that the detection effect of the formula is obvious through tests, and researches find that the use of choline chloride can obviously improve the specificity of the detection kit and has good clinical relevance with commercially available kits; meanwhile, the detection kit has wide linear range and good accuracy, for example, in the PG I detection project, the lower detection limit can reach 2ng/ml, the linear range is 2-200ng/ml, and the basis is provided for accurate clinical diagnosis. The PEG6000 and Brij35 have synergistic effect, so that the detection kit has high precision, and the repeatability and accuracy of a single measurement result can be ensured. The use of HIER-E-010 makes the detection kit have better anti-RF and HAMA interference ability, and can fully inhibit the interference effect of high-concentration RF, HAMA and other interferents. In addition, the proportion of the components is scientifically and reasonably limited, so that the components and the proportion thereof act together to obviously improve the detection performance.
The invention provides application of the buffer reagent in a latex immunoturbidimetry method or preparation of a latex immunoturbidimetry kit.
A latex immunoturbidimetry kit comprises a first reagent (R1) and a second reagent (R2), wherein the first reagent is a buffer reagent provided by the invention.
The kit adopts the buffer reagent provided by the invention as the first reagent, so that the clinical relevance is obviously improved, and the overall performance of the kit is effectively improved.
In a preferred embodiment, the second reagent comprises a buffer, a preservative, antibody-coated latex particles, a stabilizer, and an electrolyte.
In a preferred embodiment, the buffer comprises a HEPES buffer, the pH of the buffer is preferably in the range of 6-8, the concentration of the buffer is preferably 30-70 mmol/L; the concentration of the preservative is preferably 0.5-1.5 g/L; the stabilizing agent preferably comprises BSA and trehalose, wherein the concentration of the BSA is preferably 4-6g/L, and the concentration of the trehalose is preferably 35-45 g/L; the electrolyte preferably comprises sodium chloride, and the concentration of the electrolyte is preferably 150-250 mmol/L.
In a preferred embodiment, the antibody in the antibody-coated latex particle comprises antibodies PG I (pepsinogen I), PG II (pepsinogen II) or CRP (C-reactive protein), and the concentration of the antibody-coated latex particle is preferably 2-3 g/L. The antibody of the present invention may be an antibody commonly used in the art, and is not particularly limited, but is preferably a PG i antibody, a PG II antibody, or a CRP antibody, and more preferably a PG i antibody. More preferably, the PG I antibody comprises two PG I monoclonal antibodies (antibody source: Fipeng organism; antibody cargo: MABM-PG I-1-5 and MABM-PG I-2-24), which can effectively improve the sensitivity and specificity of detection.
In a preferred embodiment, the second reagent comprises: 50mmol/L HEPES buffer, 5g/L BSA, 200mmol/L NaCl, 40g/L trehalose, 2.5g/L PG I antibody coated latex particles and 1g/L Proclin 300. The inventor finds that the addition of the electrolyte sodium chloride, the stabilizing agent BSA and the trehalose in the second reagent can effectively improve the stability of the second reagent, prolong the effective period of the reagent and simultaneously facilitate the improvement of the accuracy of PG I detection. The proportion of each component in the second reagent is obtained by scientific and reasonable screening, so that the performance of the detection kit is obviously improved under the combined action of the components in the proportion.
In a more preferred embodiment, the latex particles coated with PG I antibody in the second reagent are prepared as follows: and activating the polystyrene latex microspheres by using EDC and NHS, adding the PG I antibody for incubation, and centrifuging to obtain latex particles coated by the PG I antibody.
For example, the preparation of the second reagent comprises:
(1) activation of microspheres: adding 0.1ml of a 200nm diameter polystyrene latex microsphere solution (10% concentration) into 4.5ml of 0.01M MES (pH6.0) buffer solution, adding 0.05ml of EDC (carbodiimide, 10mg/ml concentration) and 0.05ml of NHS (N-hydroxysuccinimide, 20mg/ml concentration), and activating at room temperature for 20 min;
(2) coupling of pepsinogen i antibodies: adding 0.5mg of antibody (two pepsinogen I monoclonal antibodies are mixed at a ratio of 1: 1, the monoclonal antibodies are from Fipeng organisms, the antibody cargo numbers are MABM-PG I-1-5 and MABM-PG I-2-24) into the activated solution, uniformly mixing for 2-4h at room temperature, centrifuging at 14000rpm for 30min, discarding the supernatant, uniformly mixing the precipitate with 5ml of second reagent (latex particles without antibody coating), and then ultrasonically dispersing microspheres to obtain a PG I antibody marked latex microsphere solution with the concentration of 0.1mg/ml, namely the second reagent.
In a preferred embodiment, the kit further comprises a calibrator and a quality control.
In a preferred embodiment, the dilution of the calibrator comprises buffers, surfactants, preservatives, electrolytes and stabilizers.
In a preferred embodiment, the buffer in the dilution of the calibrator comprises HEPES buffer, the pH of the buffer is preferably in the range of 6-8, and the concentration of the buffer is preferably in the range of 30-70 mmol/L; the surfactant preferably comprises Tween 20, and the concentration of the surfactant is preferably 0.5-1.5 g/L; the concentration of the preservative preferably comprises 0.5-1.5 g/L; the electrolyte preferably comprises sodium chloride, and the concentration of the electrolyte is preferably 150-250 mmol/L; the stabilizer preferably comprises BSA and disodium ethylene diamine tetraacetate, the concentration of the BSA is preferably 2-4g/L, and the concentration of the disodium ethylene diamine tetraacetate is preferably 0.5-1.5 g/L.
In a more preferred embodiment, the dilution of the calibrator comprises: 50mmol/L HEPES buffer solution, 200mmol/L sodium chloride, 3g/L BSA, 1g/L disodium ethylenediamine tetraacetic acid, 1g/L Tween 20 and 1g/L Proclin 300. The inventor finds that the effect of preparing the calibration curve is best by limiting the specific components and the proportion of the diluent, the system stability is good, the influence on detection is small, and the linear range of the calibration curve is wide.
In a preferred embodiment, the ratio of the volume amounts of the sample to be detected, the first reagent and the second reagent is (5.5-7.5): (140-160): 50.
the invention is further illustrated by the following specific examples, which, however, are to be construed as merely illustrative, and not limitative of the remainder of the disclosure in any way whatsoever.
Example 1 buffer reagents to improve the detection of clinical relevance
A buffer reagent for improving detection clinical relevance comprises the following specific components in the following table 1:
TABLE 1
Example 2 immunoturbidimetric assay kit for PG I latex
A latex immunoturbidimetric assay kit comprising a first reagent (buffer reagent in example 1), a second reagent (Table 2 below), and a PG I calibrator (dilution of calibrator is Table 3):
TABLE 2
TABLE 3
The gradient concentrations of the PG I calibrator were: 0ng/ml, 10ng/ml, 25ng/ml, 50ng/ml, 100ng/ml and 200 ng/ml.
The preparation of the second reagent comprises:
(1) activation of microspheres: adding 0.1ml of a 200nm diameter polystyrene latex microsphere solution (microspheres are purchased from JSR, concentration 10%) into 4.5ml of 0.01M MES (pH6.0) buffer, adding 0.05ml of EDC (carbodiimide, concentration 10mg/ml) and 0.05ml of NHS (N-hydroxysuccinimide, concentration 20mg/ml), and activating at room temperature for 20 min;
(2) coupling of pepsinogen i antibodies: and adding 0.5mg of antibody (two pepsinogen I monoclonal antibodies are mixed in a ratio of 1: 1, the monoclonal antibodies are from Fipeng organisms, and the products are MABM-PGI-1-5 and MABM-PGI-2-24) into the activated solution, uniformly mixing for 2-4h at room temperature, centrifuging at 14000rpm for 30min, discarding the supernatant, uniformly mixing precipitates with 5ml of a second reagent (latex particles without antibody coating), and then ultrasonically dispersing microspheres to obtain a pepsinogen I antibody marked latex microsphere solution with the concentration of 0.1mg/ml, namely the second reagent.
EXAMPLE 3 determination of Linear Range
Serum collected by a clinical standard method by using the detection kit in example 2 is used as a sample to be detected, and the reaction system is shown in the following table 4:
TABLE 4
| Adding into a cuvette | Blank tube | Calibration tube | Sample tube |
| First reagent (μ L) | 150 | 150 | 150 |
| Distilled water (mu L) | 6.5 | - | - |
| Calibrator (mu L) | - | 6.5 | - |
| Sample to be tested (μ L) | - | - | 6.5 |
| Second reagent (μ L) | 50 | 50 | 50 |
Mixing, incubating at 37 deg.C for 0.5 min and 5 min, reading absorbance A1 and A2 at 570nm, and calculating Δ A ═ A2-A1; wherein the values of the blank tube were used to prepare a calibration curve as the 0 value of the calibration curve.
The utilization concentration is as follows: calibrators of 0ng/ml, 10ng/ml, 25ng/ml, 50ng/ml, 100ng/ml and 200ng/ml gave calibration curves (results are shown in FIG. 1). And substituting the absorbance difference value of the sample to be detected into a calibration curve to obtain the content of PG I in the sample to be detected.
Reference value ranges are shown in table 5:
TABLE 5
| Serum pepsinogen results | PG positive |
| 1 is more than or equal to 70ng/mL or 1/2 is more than 3.0 | Negative (-) |
| 1 < 70ng/mL and 1/2 < 3.0 | Positive (+) |
| 1 < 50ng/mL and 1/2 < 3.0 | Positive (++) |
| 1 < 30ng/mL and 1/2 < 2.0 | Positive (+++) severe atrophy |
The PG I calibrator sample with the concentration of 110ng/mL is diluted into gradient concentration, each concentration is repeatedly measured for 3 times by using the kit provided by the invention, the average value is taken, the linear correlation coefficient is calculated with the theoretical value, the detection result is shown in Table 6, and the linear correlation is shown in FIG. 2. The corresponding linear correlation equation is shown in fig. 2, and is: 1.0221x-2.8234, correlation coefficient R2The result shows that the kit performs linear detection when the kit is 0.9976The detection range is 2-200ng/mL, and the lower detection limit can reach 2 ng/mL.
TABLE 6PG I antigen gradient concentration test results
In addition, the sensitivity and precision of the kit provided by the invention are tested, and clinical samples of 2ng/ml (low value 1), 6ng/ml (low value 2) and 64ng/ml (high value 1) are tested, and the results are shown in the following table 7:
TABLE 7
Example 4 detection of clinical relevance
The detection kit of example 2 was subjected to a sample alignment test with the PG I detection reagent of Abbott corporation (kit A), and the results of Table 8 were measured, as shown in FIG. 3, and the correlation coefficient R was determined20.9914, good correlation, can be used for clinical diagnosis.
TABLE 8
Example 5 reagent composition optimization
The buffer reagent in example 1 (the first reagent of the reagent kit in example 2) and the content and the type of the electrolyte are optimized, different choline chloride and different sodium chloride are selected as the electrolyte in the buffer reagent (the specific ratio is shown in table 9), and other components and the types of the detection reagent kit are selectedThe mixture ratio is inconvenient, the clinical relevance of the detection and the control Yapei reagent is shown in a table 10, and the statistical results of the components 1 to 8 are respectively shown in fig. 4 to 11. Analysis of the data gave the optimum salt composition and formulation with concentration component 3, i.e. the clinical relevance R when the electrolyte used in the buffer reagent was choline chloride at a concentration of 300mM2The highest is 0.9822. The use of choline chloride in buffer reagents resulted in better results of clinical relevance of the reagents compared to sodium chloride, which may be analyzed as: (1) choline chloride can block complement interference in a sample; (2) different salts in the system can lead the surfaces of the antibody, the antigen and the matrix protein to carry different electric charge quantities, and the choline chloride can better change the electric charge quantities carried by the surfaces of the antigen, the antibody and the matrix protein, improve the surface charge threshold of the protein combined with the antibody and lead the hybrid protein not to be combined with the antibody easily.
TABLE 9
In a similar manner, the other components and the mixture ratio are not changed, the type and the concentration of the blocking agent in the buffer reagent are optimized to obtain 5 groups of formula components in table 11, and the anti-RF interference performance is detected, and the result is shown in table 12.
TABLE 11
TABLE 12
Referring to the above method for optimizing the types and contents of electrolytes and blocking agents in the buffer reagent, similar experiments were also performed on other components in the buffer reagent in this example to obtain the components and the formula provided by the present invention.
Example 6 interference rejection detection
In this embodiment, the anti-interference capability of the kit in embodiment 2 on hemoglobin, bilirubin, chyle, ascorbic acid, and RF is detected, and the results are as follows: hemoglobin < 1000mg/dL (Table 15); bilirubin is less than or equal to 20mg/dL (Table 14); chyle ≤ 1000mg/dL (table 13); ascorbic acid < 50mg/dL (Table 16); the samples with RF less than or equal to 800IU/mL (Table 17) have no significant interference on PG I measurement, and the relative deviation is less than or equal to +/-10%.
TABLE 13 Lipemia interference
TABLE 14 bilirubin interference
TABLE 15 hemoglobin interference
TABLE 16 ascorbic acid interference
TABLE 17
Example 7 application of buffer reagents to clinical relevance assays for other assay items
(1) Detection reagent for pepsinogen II (latex enhanced turbidimetric immunoassay)
Pepsinogen II detection reagent R2(pH 7.5): 20mM Hepes, 150mM NaCl, 0.5% BSA, 4% sucrose, 0.1% Proclin300 and 0.1% pepsinogen II monoclonal antibody sensitized nanometer latex particles.
A comparison of R1 for the pepsinogen II assay reagents for different salt types and concentrations, the compositional formula is shown in Table 18, the results are shown in Table 19, and FIGS. 12-14:
TABLE 18 optimization of salt concentration and type in PG II reagent R1
Table 19 optimization of salt concentration and type in PG II reagent R1
And (4) conclusion: the use of choline chloride as the electrolyte in R1 has a higher clinical relevance than sodium chloride and potassium chloride in PGII agents.
(2) Detection reagent for CRP (latex enhanced immunoturbidimetry)
CRP detection reagent R2(ph 7.5): 20mM Hepes, 150mM NaCl, 0.5% BSA, 4% sucrose, 0.1% Proclin300, 0.1% CRP monoclonal antibody sensitized nano latex particles.
The results are shown in Table 21 and FIGS. 15-17, comparing R1 for CRP test reagents of different salt types and concentrations, with the formula shown in Table 20:
TABLE 20 optimization of salt concentration and type in CRP reagent R1
TABLE 21 optimization of salt concentration and type in CRP reagent R1
And (4) conclusion: among CRP agents, choline chloride, which is used as an electrolyte in R1, has a higher clinical relevance than sodium chloride and potassium chloride.
While particular embodiments of the present invention have been illustrated and described, it would be obvious that various other changes and modifications can be made without departing from the spirit and scope of the invention. It is therefore intended to cover in the appended claims all such changes and modifications that are within the scope of this invention.
Claims (10)
1. A buffer reagent for improving the clinical relevance of a test, wherein the buffer reagent comprises an electrolyte, and the electrolyte is choline chloride.
2. The buffer reagent of claim 1, wherein the concentration of choline chloride is 200-400 mmol/L;
preferably, the buffer reagent further comprises at least one of a buffer, a blocking agent, a surfactant, a sensitizer, a stabilizer, and a preservative.
3. The buffered reagent of claim 2, wherein the buffer comprises a HEPES buffer, a PB buffer, a PBS buffer, a Tris buffer, or a phosphate buffer;
preferably, the blocking agent comprises at least one of RF and HAMA binding protein, murine IgG, murine IgM, and murine serum;
preferably, the surfactant comprises Brij35, tween 20 or triton X-100;
preferably, the sensitizer comprises polyethylene glycol 4000, polyethylene glycol 6000 or polyethylene glycol 8000;
preferably, the stabilizer comprises disodium ethylenediaminetetraacetate, BSA, or trehalose;
preferably, the preservative comprises Proclin300 or sodium azide.
4. The buffer reagent according to claim 3, wherein the buffer comprises HEPES buffer or PB buffer, the pH of the buffer is preferably in the range of 6-8, and the concentration of the buffer is preferably 10-200 mmol/L;
preferably, the blocking agent comprises RF and HAMA binding protein, preferably the concentration of blocking agent is 4-6 g/L;
preferably, the RF and HAMA binding proteins include HIER-E-010;
preferably, the surfactant comprises Brij35, and the concentration of the surfactant is preferably 0.5-1.5 g/L;
preferably, the sensitizer comprises PEG6000, and the concentration of the sensitizer is preferably 15-25 g/L;
preferably, the stabilizer comprises disodium ethylene diamine tetraacetate, and the concentration of the stabilizer is preferably 0.5-1.5 g/L;
preferably, the concentration of the preservative is 0.5-1.5 g/L.
5. Use of a buffer reagent according to any one of claims 1 to 4 in latex immunoturbidimetry or in the preparation of a latex immunoturbidimetry kit.
6. A latex immunoturbidimetric kit comprising a first reagent and a second reagent, the first reagent being a buffer reagent according to any of claims 1 to 4.
7. The kit of claim 6, wherein the second reagent comprises a buffer, a preservative, antibody-coated latex particles, a stabilizer, and an electrolyte;
preferably, the buffer comprises a HEPES buffer, the pH of the buffer is preferably in the range of 6-8, and the concentration of the buffer is preferably 30-70 mmol/L;
preferably, the concentration of the preservative is 0.5-1.5 g/L;
preferably, the stabilizing agent comprises BSA and trehalose, wherein the concentration of the BSA is preferably 4-6g/L, and the concentration of the trehalose is preferably 35-45 g/L;
preferably, the electrolyte comprises sodium chloride, and the concentration of the electrolyte is preferably 150-250 mmol/L.
8. The kit of claim 6, wherein the antibody-coated latex particle antibody comprises a PG I antibody, a PG II antibody or a CRP antibody;
preferably, the concentration of the antibody-coated latex particles is 2-3 g/L.
9. The kit of any one of claims 6 to 8, wherein the kit further comprises a calibrator and a quality control.
10. The kit of claim 9, wherein the dilution of the calibrator comprises buffers, surfactants, preservatives, electrolytes, and stabilizers;
preferably, the buffer comprises a HEPES buffer, the pH of the buffer is preferably in the range of 6-8, and the concentration of the buffer is preferably 30-70 mmol/L;
preferably, the surfactant comprises tween 20, and the concentration of the surfactant is preferably 0.5-1.5 g/L;
preferably, the concentration of the preservative comprises 0.5-1.5 g/L;
preferably, the electrolyte comprises sodium chloride, and the concentration of the electrolyte is preferably 150-250 mmol/L;
preferably, the stabilizing agent comprises BSA and disodium ethylene diamine tetraacetate, the concentration of the BSA is preferably 2-4g/L, and the concentration of the disodium ethylene diamine tetraacetate is preferably 0.5-1.5 g/L.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911132994.1A CN112816698A (en) | 2019-11-18 | 2019-11-18 | Buffer reagent for improving detection clinical correlation and latex immunoturbidimetry kit |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911132994.1A CN112816698A (en) | 2019-11-18 | 2019-11-18 | Buffer reagent for improving detection clinical correlation and latex immunoturbidimetry kit |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112816698A true CN112816698A (en) | 2021-05-18 |
Family
ID=75852920
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911132994.1A Pending CN112816698A (en) | 2019-11-18 | 2019-11-18 | Buffer reagent for improving detection clinical correlation and latex immunoturbidimetry kit |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112816698A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114594269A (en) * | 2022-03-16 | 2022-06-07 | 安徽伊普诺康生物技术股份有限公司 | Serum amyloid A detection kit and preparation method thereof |
| CN114740209A (en) * | 2022-06-13 | 2022-07-12 | 深圳市帝迈生物技术有限公司 | D-dimer buffer reagent with sample diluent function |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103698525A (en) * | 2014-01-09 | 2014-04-02 | 北京万泰德瑞诊断技术有限公司 | Latex immunoturbidimetry pepsinogen I detection kit for eliminating chyle interference |
| CN103713140A (en) * | 2014-01-09 | 2014-04-09 | 北京万泰德瑞诊断技术有限公司 | Latex immunoturbidimetry type pepsinogen II detection kit capable of eliminating chyle interference |
| CN104049085A (en) * | 2013-03-13 | 2014-09-17 | 苏州德沃生物技术有限公司 | CRP latex-reinforced immunonephelometry reagent, its kit and use of kit |
| CN108535491A (en) * | 2018-03-22 | 2018-09-14 | 北京九强生物技术股份有限公司 | A kind of latex enhancing immune of Troponin I is than turbid detection kit |
| CN109580925A (en) * | 2018-10-23 | 2019-04-05 | 东软威特曼生物科技(南京)有限公司 | A kind of recombination reaction promotor for external diagnosis reagent |
-
2019
- 2019-11-18 CN CN201911132994.1A patent/CN112816698A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104049085A (en) * | 2013-03-13 | 2014-09-17 | 苏州德沃生物技术有限公司 | CRP latex-reinforced immunonephelometry reagent, its kit and use of kit |
| CN103698525A (en) * | 2014-01-09 | 2014-04-02 | 北京万泰德瑞诊断技术有限公司 | Latex immunoturbidimetry pepsinogen I detection kit for eliminating chyle interference |
| CN103713140A (en) * | 2014-01-09 | 2014-04-09 | 北京万泰德瑞诊断技术有限公司 | Latex immunoturbidimetry type pepsinogen II detection kit capable of eliminating chyle interference |
| CN108535491A (en) * | 2018-03-22 | 2018-09-14 | 北京九强生物技术股份有限公司 | A kind of latex enhancing immune of Troponin I is than turbid detection kit |
| CN109580925A (en) * | 2018-10-23 | 2019-04-05 | 东软威特曼生物科技(南京)有限公司 | A kind of recombination reaction promotor for external diagnosis reagent |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114594269A (en) * | 2022-03-16 | 2022-06-07 | 安徽伊普诺康生物技术股份有限公司 | Serum amyloid A detection kit and preparation method thereof |
| CN114594269B (en) * | 2022-03-16 | 2022-10-18 | 安徽伊普诺康生物技术股份有限公司 | Serum amyloid A detection kit and preparation method thereof |
| CN114740209A (en) * | 2022-06-13 | 2022-07-12 | 深圳市帝迈生物技术有限公司 | D-dimer buffer reagent with sample diluent function |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6162645A (en) | Determination of % glycated hemoglobin | |
| CN109725160B (en) | Procalcitonin (PCT) detection kit | |
| CN105842458A (en) | Procalcitonin detection kit, and method of measuring content of procalcitonin therewith | |
| CA1247523A (en) | Method for reducing non-specific interferences in agglutination immunoassays | |
| CN101893619B (en) | Method for improving stability of latex suspension liquid | |
| CN112816698A (en) | Buffer reagent for improving detection clinical correlation and latex immunoturbidimetry kit | |
| CN110806487A (en) | Kit for detecting human heparin binding protein and preparation method thereof | |
| CN111562372B (en) | Latex enhanced immunoturbidimetry kit for detecting creatine kinase isoenzyme CK-MB | |
| US6316265B1 (en) | Determination of % glycated hemoglobin | |
| CN113136269A (en) | Cleaning solution for chemiluminescence immunoassay | |
| CN112255416A (en) | Kit for quantitatively detecting HBP (hepatitis B protein) by using magnetic particle chemiluminescence as well as preparation and detection methods thereof | |
| CN111381027A (en) | Immunocapture composition, preparation method and application thereof, and immunoassay kit | |
| CN108663526B (en) | Secondary antibody competes immunoturbidimetry assay kit and its making and use method | |
| CN110596405A (en) | Kit for detecting content of heart-type fatty acid binding protein by latex enhanced immunoturbidimetry | |
| CN114487420A (en) | Creatine kinase isoenzyme detection kit | |
| CN105988003B (en) | A kind of whole process c reactive protein assay kit and its application | |
| CN103529221A (en) | Kit for detecting acid glycoprotein content in serum | |
| CN111239404B (en) | Detection kit capable of simultaneously detecting retinol binding protein in urine sample and serum sample | |
| CN110736839A (en) | Latex-enhanced immunoturbidimetric assay kit for cytokeratin 19 fragments | |
| CN115236325A (en) | Kit for determining CTX (CTX) by latex enhanced immunoturbidimetry and preparation and detection method thereof | |
| CN113125749A (en) | Kit for detecting serum glycated albumin | |
| CN114137204A (en) | KL-6 determination kit and preparation and detection methods thereof | |
| CN112129934A (en) | Ferritin detection kit and preparation method thereof | |
| US5962340A (en) | Homogeneous immunoassay method utilizing 5-300 mM magnesium | |
| Murthy et al. | Activity concentration and mass concentration (monoclonal antibody immunoenzymometric method) compared for creatine kinase MB isoenzyme in serum. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |